Table 2 Seroprevalence to P. vivax and P. falciparum at quarterly surveys
|  | Quarter 1 (May–July) | Quarter 2 (August–October) | Quarter 3 (November–January) | Quarter 4 (February–April) | ||||
|---|---|---|---|---|---|---|---|---|
Number positive | Seroprevalence% (95% CI) | Number positive | Seroprevalence % (95% CI) | Number positive | Seroprevalence % (95% CI) | Number positive | Seroprevalence % (95% CI) | |
P. vivax | ||||||||
 Age group | ||||||||
  1–15 years old | 44 | 12.1 (8.0–17.8) | 24 | 11.2 (7.6–16.2) | 26 | 17.6 (12.2–24.6) | 9 | 10.5 (5.5–18.9) |
  > 15 years old | 1014 | 41.0 (38.9–43.1) | 1000 | 50.1 (47.9–52.3) | 906 | 41.6 (39.6–43.7) | 918 | 41.8 (39.8–43.9) |
  All ages | 1058 | 38.8 (36.8–40.8) | 1024 | 46.3 (44.2–48.3) | 932 | 40.1 (38.2–42.1) | 927 | 40.7 (38.7–42.7) |
P. falciparum | ||||||||
 Age group | ||||||||
  1–15 years old | 6 | 3.4 (1.6–7.5) | 8 | 3.7 (1.9–7.3) | 5 | 3.4 (1.4–7.9) | 1 | 1.2 (0.2–7.8) |
  > 15 years old | 405 | 18.8 (17.3–20.6) | 521 | 26.1 (24.2–28.1) | 489 | 22.6 (20.9–24.4) | 504 | 23.0 (21.3–24.8) |
  All ages | 411 | 17.7 (16.2–19.3) | 529 | 23.9 (22.2–25.7) | 494 | 21.4 (19.8–23.1) | 505 | 22.1 (20.5–23.9) |